Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 3, 1997, Pages 323-329

  Goss, G ^a   Szer, J ^a   Basser, R ^a   Fox, R ^a   Grigg, A ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Autologous stem cell transplantation; Lymphoma; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC AGENT; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HODGKIN DISEASE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; REMISSION; STEM CELL TRANSPLANTATION;

EID: 0030802241     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb01986.x     Document Type: Article

References (31)

1. Armitage JO. Treatment of non Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023-30.
2. De Vita Jr V, Hubbard SM. Drug therapy: Hodgkin's disease. N Engl J Med 1993; 528: 560-5.
3. Valasquez W, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high dose ara-c and dexamethasone (DHAP). Blood 1988; 71: 117-22.
4. Cabanillas F, Hagemister F, McLaughlin P et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5: 407-12.
5. Wilson WH, Bryant G, Bates S et al. EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-82.
6. Buzzoni R, Colleoni M, Bajetta E et al. Effective salvage chemotherapy in relapsed or refractory non Hodgkin's lymphoma. Ann Oncol 1993; 4: 251-3.
7. Ho A, Del Valle F, Ruckle H et al. Mitoxantrone and high dose cytarabine as salvage therapy for refractory non Hodgkin's lymphoma. Cancer 1989; 64: 1388-92.
8. Warrell R, Danieo L, Coonley C et al. Salvage chemotherapy of advanced lymphoma with investigational drugs: mitoxantrone, gallium nitrate and etoposide. Cancer Treat Rep 1987; 71: 47-51.
9. Cabanillis F. Experience with salvage regimens at MD Anderson hospital. Ann Oncol 1991; 2: 31-2.
10. Takvorian T, Canallos GP, Ritz, J et al. Prolonged disease free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with poor prognosis. N Engl J Med 1987; 316: 1499-505.
11. Freedman AS, Nadler LM. Which patients with relapsed non-Hodgkin's lymphoma benefit from high dose therapy and hematopoietic stem cell transplantation? J Clin Oncol 1993; 11: 1842-3.
12. Gribben JG, Goldstone AH, Linch DC et al. Effectiveness of high dose combination chemotherapy and autologous hone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional dose therapy. J Clin Oncol 1989; 7: 1621-9.
13. Peterson FB, Applebaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-47.
14. Vose JM, Armitage JO, Bierman S et al. Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation. Am J Med 1989; 87: 285-8.
15. Brandwein JM, Callum J, Sutcliffe SB et al. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 1990; 5: 99-103.
16. Longo DL, De Vita VT, Jaffe ES et al. Lymphocytic lymphomas. In: De Vita VT, Hellman S, Rosenberg SA (Eds). Cancer. Principles and practice of oncology, 4th edn. Philadelphia: J. B. Lippincott Co, 1993; 1859-927.
17. Sparano JA, Wiernik PH, Trager M et al. Infusional cyclophosphamide (C), doxorubicin (D) and etoposide (E): An active regimen in relapsed non Hodgkin's lymphoma. Proc ASCO 1991; 10: 286.
18. Sparano JA, Wiernik PH, Strack M et al. Infusional cyclophosphamide, doxorubicin, and etoposide in Human Immunodeficiency Virus and Human T Cell Leukaemia Virus Type I-related non-Hodgkin's lymphoma: A highly active regimen. Blood 1993; 81: 2810-5.
19. Sparano JA, Wiernik PH, Leaf A et al. Infusional cyclophosphamide, doxorubicin and etoposide in relapsed and resistant non Hodgkin's lymphoma: Evidence for a schedule-dependent effect favouring infusional administration of chemotherapy. J Clin Oncol 1993; 11: 1071-9.
20. Slevin ML, Clark PI, Joel SP et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989; 7: 1333-9.
21. Druckrey H. Theoretical use of chemotherapy in the treatment of carcinoma. J Kanser (Ankara) 1970; 1: 130-49.
22. Goldin A, Venditti JM, Kline I. Preclinical investigations with ifosfamide in relation to cyclophosphamide. In: Burkert H, Voight HC (Eds). Proceedings of the International Holoxan Symposium. Dusseldorf, Germany, 1977; 19-28.
23. Chresta CM, Hicks R, Hartley JA et al. Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non cytotoxic concentrations of arabinosyl cytosine. Cancer Chemother Pharmacol 1992; 31: 139-45.
24. Lorico A, Boiocchi M, Rappa G et al. Increase in topoisomerase - II mediated DNA breaks and cytotoxicity of VP-16 in human U937 lymphoma cells pretreated with low doses of methotrexate. Int J Cancer 1990; 45: 15-162
25. Lickliter J, Begley G, Boyd A et al. Combined chemotherapy and granulocyte colony-stimulating factor mobilise large numbers of peripheral blood progenitor cells in pretreated patients. Leukaemia and Lymphoma (in press).
26. Srivastava A, Bradstock KF, Szer J et al. Busulphan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 1993; 12: 323-9.
27. Grigg A, Goss G. Phase I dose escalation study of 5 days continuous infusion of VP16 plus busulphan/cyclophosphamide as a conditioning regimen prior to autologous transplantation. Aust NZ J Med 1995; 25: 71 (Abstr).
28. Gribben JG, Linch DC, Singer DRJ et al. Successful treatment of refractory Hodgkin's disease by high dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-4.
29. Kaplan EL, Meier P. Non parametic estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
30. Ahmed T, Feldman E, Ciavarella P et al. Sequential autologous bone marrow transplantation for high risk Hodgkin's disease. Proc ASCO 1991; 10: 223.
31. Tourani J, Levy R, Colonna P et al. High dose chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol 1992; 10: 1086-94.